^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Brukinsa (zanubrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
Anticancer effect of zanubrutinib in HER2-positive breast cancer cell lines
Published date:
02/24/2023
Excerpt:
The anticancer effect of the BTK inhibitors ibrutinib, acalabrutinib, tirabrutinib, evobrutinib and zanubrutinib was evaluated in a panel of ten breast cancer cell lines in vitro....In contrast, four HER2-positive cell lines were found to be sensitive to ibrutinib, zanubrutinib and acalabrutinib, with submicromolar GI50 values ranging from 0.09 μM to 0.88 μM for ibrutinib and zanubrutinib and single-digit micromolar GI50 values for acalabrutinib.
DOI:
https://doi.org/10.1101/2023.02.23.529815